Insider · CIK 0001875620

Sands Capital Life Sciences Pulse Fund II, L.P.

owner

Files at IKT (Inhibikase Therapeutics, Inc.). First filing Nov 24, 2025, latest Nov 24, 2025.

Track record

Not enough history

Fewer than three past buys with six months of prices.

Median 6-month excess

after past buys, n = 0

Hit rate

past buys that beat the index over 6 months

Open-market trades

1 / 0

$3.0M bought, $0 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

IKT: Inhibikase Therapeutics, Inc.

IKTOct 9, 2026 · close 1.97

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

Score	Company	Value	Holdings	Price context	Filed
53Moderate	IKTbuy Inhibikase Therapeutics, Inc.	$3.0M 2,068,965 shares	+19%	+4% from low-62% from high	Nov 24, 2025

Transactions

Every row this insider has filed, newest first.

Date	Company	Transaction	Shares	Price	Value	Holdings after	Filed
Nov 21, 2025	IKT Inhibikase Therapeutics, Inc.	POpen-market purchase Common Stock	+2,068,965	$1.45	$3.0M	13,018,965	Nov 24, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.